Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors

S-1, an oral pyrimidine fluoride-derived agent, is effective against various cancers. Sorafenib, an oral multikinase inhibitor, was found to prolong the survival of various cancers and enhance the cytotoxicity of chemotherapeutic agents. We conducted a phase I dose escalation study to determine dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Hui-Jen, Shiah, Her-Shyong, Chang, Jang-Yang, Su, Wu-Chou, Chiang, Nai-Jung, Chen, Li-Tzong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921110/
https://www.ncbi.nlm.nih.gov/pubmed/33649501
http://dx.doi.org/10.1038/s41598-021-84279-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921110/
https://www.ncbi.nlm.nih.gov/pubmed/33649501
http://dx.doi.org/10.1038/s41598-021-84279-6

Ejemplares similares